Ratings BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Real-time Estimate Cboe BZX Other stock markets 15:52:51 16/05/2024 BST			5-day change	1st Jan Change
0.615 ^USD	-0.32%		-10.52%	-60.96%

04-17	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
04-10	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOLINERX LTD.	-60.96%	53.23M	-
VERTEX PHARMACEUTICALS INCORPORATED	+7.24%	113B	B+
REGENERON PHARMACEUTICALS, INC.	+10.86%	106B	B+
ARGENX SE	+0.87%	22.27B	B
BIONTECH SE	-12.17%	22.22B	B+
GENMAB A/S	-5.57%	19.43B	A-
WUXI APPTEC CO., LTD.	-37.85%	17.87B	A-
BEIGENE, LTD.	-5.30%	17.24B	B
NEUROCRINE BIOSCIENCES, INC.	+7.18%	14.29B	C+
SAREPTA THERAPEUTICS, INC.	+35.14%	12.52B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes